{"id":"NCT03777657","sponsor":"BeiGene","briefTitle":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-13","primaryCompletion":"2023-02-28","completion":"2024-08-27","firstPosted":"2018-12-17","resultsPosted":"2025-02-14","lastUpdate":"2025-02-14"},"enrollment":997,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Gastric, or Gastroesophageal Junction Adenocarcinoma"],"interventions":[{"type":"DRUG","name":"Tislelizumab","otherNames":["BGB-A317","TEVIMBRA®"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":[]},{"type":"DRUG","name":"5-Fluorouracil","otherNames":[]}],"arms":[{"label":"Tislelizumab + Chemotherapy","type":"EXPERIMENTAL"},{"label":"Placebo + Chemotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.","primaryOutcome":{"measure":"Overall Survival in PD-L1 Positive Participants","timeFrame":"From randomization up to the primary analysis data cut-off date of 8 October 2021; Median (range) time on follow-up was 11.8 (0.1 - 33.4) months.","effectByArm":[{"arm":"Tislelizumab + Chemotherapy","deltaMin":17.2,"sd":null},{"arm":"Placebo + Chemotherapy","deltaMin":12.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0056"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":149,"countries":["United States","China","France","Italy","Japan","Poland","Puerto Rico","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["40528576","40075025","38923910","38806195"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":211,"n":498},"commonTop":["Nausea","Decreased appetite","Anaemia","Platelet count decreased","Vomiting"]}}